Physician profile
Priya Pillutla
NPI 1255453171
$3,973.72
in general payments reported to CMS, 2019-2025
26 companies · $577 in 2025
The $577 reported for 2025 was more than what a typical Adult Congenital Heart Disease provider received nationally (typical 2025 total: $272).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $138 · 2021: $437 · 2022: $757 · 2023: $969 · 2024: $796 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $889.65 | 2019-2025 | Uptravi, Opsumit |
| Boston Scientific Corporation | $669.16 | 2022-2025 | Rotapro, Mamba, Avvigo Guidance System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $333.08 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $222.76 | 2025 | |
| Pfizer INC. | $199.53 | 2019-2024 | |
| Edwards Lifesciences Corporation | $187.03 | 2022 | |
| Inspire Medical Systems, INC. | $179.18 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $169.45 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $152.85 | 2023-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $142.85 | 2023 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $121.00 | 2023-2024 | |
| Amgen INC. | $111.70 | 2019-2023 | Repatha |
| Astellas Pharma US INC | $102.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.95 | 2022-2023 | Jardiance |
| Scpharmaceuticals INC. | $59.76 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $58.50 | 2022-2023 | Definity |
| Kiniksa Pharmaceuticals International, Plc | $49.29 | 2024 | Arcalyst |
| Abbott Laboratories | $43.63 | 2021 | |
| Novo Nordisk INC | $38.72 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $37.60 | 2021 | |
| United Therapeutics Corporation | $30.47 | 2022 | |
| Medtronic Vascular, INC. | $27.69 | 2020 | |
| Philips North America LLC | $20.33 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $19.49 | 2022 | |
| Teleflex LLC | $12.32 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Pillutla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.